2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
11/08/18Chiasma Reports Third Quarter 2018 Results
Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient in Phase 3 MPOWERED™ Trial of Octreotide Capsules and Elects to Resume Enrollment of up to an Additional 15 U.S. Patients to Expand Endocrinologist Experience with Octreotide Capsules in the U.S. Cash sufficient to fund operations through at least the anticipated release of top-line CHIASMA OPTIMAL data while supporting th... 
Printer Friendly Version
11/01/18Chiasma Supports Acromegaly Awareness Day
Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognizes November 1st as Acromegaly Awareness Day.    “Today, we acknowledge the acromegaly patients, their families and advocates, as well as the clinical thou... 
Printer Friendly Version
10/17/18Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association
Presentation by Dr. Maria Fleseriu, a widely-published endocrinologist and recognized thought leader in the field of acromegaly WALTHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced an Oral Presentation at the 18th Congress of the European Neuroendocrine Association (ENEA), which is being held October 17-20 in Wrocław, Poland... 
Printer Friendly Version
10/01/18Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
Topline data now expected in September 2019, versus prior guidance of 4Q 2019 WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has completed enrollment of its international Phase 3 clinical trial, referred to as CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers). This trial is be... 
Printer Friendly Version
09/13/18Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies
Among the initial findings, some acromegaly patients managed by injectable somatostatin receptor ligands (SRLs) report symptoms that may interfere with daily life Treatment burden associated with injectable SRLs underscores need for an alternative administered treatment option Screening data generated from Chiasma’s ongoing MPOWERED™ randomized Phase 3 trial of its investigational octreotide capsules product candidate, conditionally trade-named, MYCAPSSA® WALTHAM, Mass., Sept. 13, 2018 (... 
Printer Friendly Version
08/29/18Chiasma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Mark Fitzpatrick, Chief Executive Officer and William Ludlam, MD, PhD, Senior VP of Clinical Development and Medical Affairs, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, being held September 4-6, 2018 at the St. Regis Hote... 
Printer Friendly Version
08/09/18Chiasma Reports Second Quarter 2018 Results
Recent Highlights Include Completion of Enrollment of MPOWERED Phase 3 Trial and 50% Randomization in CHIASMA OPTIMAL Phase 3 Trial WALTHAM, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “We have made meaningful progress on our plan to a... 
Printer Friendly Version
07/25/18Chiasma Completes Enrollment of MPOWERED(TM) Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
Chiasma Anticipates Trial Completion in Q4 2019 and Release of Top-line MPOWERED Data by Early 2020 WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has successfully enrolled 135 acromegaly patients into the six-month run-in phase of its international Phase 3 clinical trial referred to as MPOWERED (Maintenance of Acrom... 
Printer Friendly Version
06/18/18Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference
WALTHAM, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Drs. William Ludlam and Asi Haviv will present at the 12th Acromegaly Consensus Conference on June 19th in Prague. The presentation is titled “New Methodologies in Acromegaly Clinical Trial Design – Octreotide Capsules, a Case Study.” Pharmacologic treatment of acromeg... 
Printer Friendly Version
06/14/18Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
Company Expects Randomization to be Completed by End of 2018 and Anticipates Release of Top-line Data in Q4 2019 WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has achieved 50% patients randomized in its international Phase 3 clinical trial, referred to as “CHIASMA OPTIMAL” (Octreotide capsules vs. Placebo Treatment In... 
Printer Friendly Version
05/14/18Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial
Conference call and webcast scheduled for 5 p.m. ET today WALTHAM, Mass., May 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has reached agreement with the U.S. Food and Drug Administration (FDA) to redefine certain secondary endpoints of its recently initiated CHIASMA OPTIMAL Phase 3 clinical trial for its octreotide capsules product cand... 
Printer Friendly Version
05/10/18Chiasma Reports First Quarter 2018 Results
MYCAPSSA Phase 3 trials progressing on track WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the first quarter ended March 31, 2018. “We continue to execute on our plan to advance octreotide capsules, conditionally trade-named MYCAPSSA®, as a maintenance treatment for adult patients with acromegaly,”... 
Printer Friendly Version
03/20/18Chiasma Reports Fourth Quarter and Year End 2017 Results
Chiasma Now Estimates Approximately 130 Patients Will Be Required to Enter Run-in Phase of MPOWERED Phase 3 Clinical Trial, Versus Previous Estimate of Up to 150 Patients WALTHAM, Mass., March 20, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the fourth quarter and year ended December 31, 2017. Chiasma also announced it now ... 
Printer Friendly Version
03/16/18Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly
WALTHAM, Mass., March 16, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a poster presentation of the CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers) Phase 3 clinical trial design at ENDO 2018: The Endocrine Society’s 100th Annual Meeting & Expo at 1 p.m. CT on March 18, 2018 at McCormick Place in Chicago. ... 
Printer Friendly Version
03/05/18Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Mark Fitzpatrick, president and CEO, and Dr. William Ludlam, SVP, clinical development and medical affairs, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 4:10 p.m. ET. A live and archived audio webcast of the pre... 
Printer Friendly Version
02/28/18Chiasma Honors Patients, Researchers for Rare Disease Day 2018
WALTHAM, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its support for the patient and research communities in recognition of Rare Disease Day 2018. “At Chiasma, we are focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases,” said Mark Fitzpatr... 
Printer Friendly Version
01/08/18Chiasma Reports on Significant Progress Made During 2017
Initiated CHIASMA OPTIMAL Phase 3 Clinical Trial after SPA agreement with FDA Announces expected year-end 2017 cash and investments balance of approximately $67 million Continues to expect existing cash and investments to be sufficient to fund operations through anticipated release of top-line data from CHIASMA OPTIMAL Phase 3 Clinical Trial by the end of 2019 WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company fo... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.